Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)

Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)

Individualization of treatment goals is a modern trend in diabetology. During 47th Annual Meeting of European Association for the Study of Diabetesthis very problem was addressed repeatedly. The Sanofi Satellite Symposium under the name A step towards individualizing care to achieve earlyand sustain...

Full description

Bibliographic Details
Main Authors:	Ivona Renata Yarek-Martynova, Lyubov' Leonidovna Bolotskaya
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2011-12-01
Series:	Сахарный диабет
Subjects:	easd diabetes mellitus insulin glargin insulin glulisin insulin therapy exenatide lixisenatide
Online Access:	https://dia-endojournals.ru/dia/article/viewFile/5830/3589

Similar Items

The 47th Annual meeting of the European Association for the Study of Diabetes (EASD), 12-16 September, Lisbon
by: Anatoliy Gennad'evich Kuz'min, et al.
Published: (2011-09-01)

Modern aspects of diabetes care (following 48th Annual Meeting of the European Association for the Studyof Diabetes), October 1th-5th, 2012, Berlin, Germany
by: Olga Konstantinovna Vikulova, et al.
Published: (2012-12-01)

46rd Congress of European Association for the Study of Diabetes (EASD), 20-24 September 2010, Stokholm
by: Inna Igorevna Klefortova
Published: (2010-09-01)

Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
by: Edwards KL, et al.
Published: (2006-09-01)

Should Type 2 Diabetes Management Be More of a Priority in Post-Acute Coronary Syndrome Patients?
by: Ele Ferrannini, et al.
Published: (2015-11-01)

Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2
by: S. V. Nedogoda, et al.
Published: (2020-01-01)

Economic evaluation of insulin therapy intensification for effective and safe control of diabetes mellitus type 2
by: A. S. Kolbin, et al.
Published: (2019-10-01)

Health technology assessement of the fxed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensifcation of diabetes mellitus type 2
by: S. К. Zyryanov, et al.
Published: (2019-01-01)

A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose
by: Kress S, et al.
Published: (2021-03-01)

Economic analysis of Lixisenatide in Diabetes Mellitus Type 2
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Investigating the Different Dimensions of DPP-4 Inhibitors
by: Heinz Drexel, et al.
Published: (2014-10-01)

Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial
by: Ting-Ting Yin, et al.
Published: (2018-10-01)

Vozmozhnosti kletochnykh tekhnologiy v lechenii sakharnogo diabeta
by: Tatiana Vasil'evna Nikonova, et al.
Published: (2008-12-01)

Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen
by: N V Efremova, et al.
Published: (2015-10-01)

Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
by: Oliver Schnell, et al.
Published: (2018-02-01)

Economic perspectives for effective control of diabetes mellitus type 2 with fixed combination of basal insulin analog and GLP-1 agonist
by: S. K. Zyryanov, et al.
Published: (2019-10-01)

Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis
by: Karla F. S. Melo, et al.
Published: (2019-01-01)

Is it Time to Transform Our Treatment Of Type 2 Diabetes
by: Michael Nauck, et al.
Published: (2013-10-01)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
by: Lau IT, et al.
Published: (2017-06-01)

Effective and safe control of glycemia with insulin Apidra - the recipe for success of type 2 diabetes prophylaxis
by: Elena Valer'evna Biryukova
Published: (2011-12-01)

Análogos de insulina Insulin analogues
by: Manuel E. Licea Puig
Published: (2006-12-01)

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
by: Rendell M
Published: (2017-04-01)

Kontrol altında olmayan tip 2 diyabetes mellitus hastalarında insülin tedavisinden eksenatid bazlı tedaviye geçişin etkinliği
by: Cem Onur Kıraç, et al.
Published: (2020-09-01)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
by: Courtney H, et al.
Published: (2017-03-01)

Insulin choice in feline diabetes mellitus
by: Yaiza Gomez Mejias
Published: (2021-08-01)

Mauriac syndrome in adult with type 1 diabetes mellitus
by: Natalya Alexandrovna Molitvoslovova, et al.
Published: (2011-09-01)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
by: Xiaoli Sheng, et al.
Published: (2019-08-01)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
by: Kai‐Jen Tien, et al.
Published: (2019-05-01)

Forum for injection techniques, India: The first Indian recommendations for best practice in insulin injection technique
by: Sanjay Kalra, et al.
Published: (2012-01-01)

Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide
by: M. V. Martjanova, et al.
Published: (2020-05-01)

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020-05-01)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
by: Dippel, Franz-Werner, et al.
Published: (2010-01-01)

Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
by: L. N. Shitov, et al.
Published: (2019-04-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
by: Kun-Ho Yoon, et al.
Published: (2017-12-01)

Untersuchungen zur Wirtschaftlichkeit langwirksamer Insuline bei Patienten mit insulinbehandeltem Typ-2-Diabetes mellitus in Deutschland
by: Dippel, Franz-Werner
Published: (2013)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
by: Shafie AA, et al.
Published: (2020-06-01)

A Pilot Study of a Comparison of Glycemic Control in Critically Ill Patients
by: Rungsun Bhurayanontachai, et al.
Published: (2010-10-01)

Intensive Insulin Titration with Insulin Glargine in Insulin-Naive Type 2 Diabetic Patients in Turkey: LANTIT Study
by: Ercan Tuncel, et al.
Published: (2015-09-01)

Lantus solostar in real life medical practice
by: Florenţiu Ariel, et al.
Published: (2014-03-01)